WVE Stock Cash Flow Statements

Wave Life Sciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Wave Life Sciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31

cash flows from operating activities
net income	-50,469,000	-46,878,000	29,253,000	-61,780,000	-32,923,000	-31,558,000	-16,256,000	7,252,000	-21,104,000	-27,405,000	-43,709,000	-39,004,000	-41,296,000	-37,814,000	-34,785,000	-6,230,000	-38,766,000	-42,464,000	-28,789,000	-33,100,000	-40,528,000	-47,493,000	-56,770,000	-50,726,000	-41,942,000	-44,200,000	-37,887,000	-37,631,000	-35,894,000	-35,241,000	-30,211,000	-26,135,000	-24,693,000	-20,996,000	-18,454,000	-17,535,000	-11,565,000	-7,847,000	-7,099,000
adjustments to reconcile net income to net cash from operating activities:
amortization of right-of-use assets	1,331,000	1,289,000	1,249,000	1,210,000	1,173,000	1,135,000	1,101,000	1,067,000	1,033,000	1,005,000	983,000	964,000	809,000	784,000	759,000	550,000	531,000	512,000	493,000	476,000	458,000	442,000	426,000	411,000	395,000	381,000
depreciation of property and equipment	865,000	875,000	907,000	948,000	999,000	1,042,000	1,081,000	1,197,000	1,289,000	1,433,000	1,512,000	1,637,000	1,695,000	1,730,000	1,779,000	1,847,000	1,909,000	1,948,000	2,017,000	2,034,000	2,024,000	2,039,000	2,004,000	1,947,000	1,854,000	1,783,000	1,714,000	1,458,000	1,234,000	1,175,000		595,000	356,000	315,000
share-based compensation expense	6,196,000	4,953,000	3,244,000	3,531,000	3,485,000	2,881,000	2,352,000	2,284,000	2,409,000	2,750,000	2,907,000	3,366,000	6,950,000	3,971,000	3,726,000	5,896,000	2,722,000	4,063,000	3,219,000	3,284,000	3,794,000	3,999,000	4,987,000	5,020,000	5,157,000	4,345,000	4,011,000	3,610,000	3,545,000	4,430,000	3,177,000	3,000,000	2,967,000	2,999,000	2,528,000	2,183,000	1,270,000	866,000	814,000
changes in operating assets and liabilities:
accounts receivable	-1,617,000	1,422,000	-1,422,000	1,290,000	-1,290,000	21,086,000	-14,086,000								22,500,000	-22,500,000			0	0	0	20,000,000	0	0			0	5,000,000											0
prepaid expenses	1,362,000	1,482,000	1,028,000	1,575,000	-1,008,000	-1,227,000	-2,398,000	1,498,000	219,000	-1,299,000	-513,000	-2,023,000	1,544,000	-356,000	1,043,000	1,561,000	1,242,000	4,000	-2,468,000	-1,514,000	3,547,000	-373,000
other assets	-199,000	118,000	-4,214,000	2,389,000	-6,000	-1,394,000	91,000	272,000	-569,000	-1,804,000	-109,000	5,449,000	-1,095,000	-851,000	-1,385,000	4,522,000	-1,760,000	-1,715,000	-985,000	15,257,000	1,832,000	-1,983,000
accounts payable	276,000	-2,052,000	3,460,000	-5,078,000	6,107,000	-1,068,000	192,000	503,000	218,000	-4,674,000	1,011,000	5,073,000	774,000	2,490,000	-232,000	-1,084,000	-4,785,000	-466,000	4,555,000	-4,200,000	-2,574,000	7,336,000	-10,968,000	8,431,000	-1,743,000	783,000	2,135,000	3,113,000	-702,000	390,000	3,268,000	-1,061,000	668,000	1,017,000	1,470,000	716,000	1,479,000	-296,000	-816,000
accrued expenses and other current liabilities	5,213,000	-13,268,000	6,939,000	3,465,000	4,056,000	-10,207,000	4,204,000	2,195,000	2,807,000	-9,930,000	6,496,000	-29,000	4,156,000	-7,932,000	3,497,000	1,441,000	3,262,000	-5,310,000	1,789,000	1,962,000	-2,774,000	-5,191,000	2,446,000	2,106,000	3,363,000	-6,467,000	5,217,000	1,416,000	1,772,000	-2,541,000	2,652,000	1,734,000	701,000	-537,000	-188,000	1,276,000	879,000	329,000	340,000
deferred revenue	-7,082,000	-9,175,000	-82,326,000	7,677,000	-6,402,000	-12,538,000	-7,971,000	-42,042,000	-22,107,000	126,448,000	-1,239,000	-151,000	-271,000	-1,584,000	-1,765,000	-13,923,000			-9,439,000	-3,450,000	-3,027,000	-4,161,000	-2,400,000	-2,929,000	-7,628,000	-3,026,000	-3,622,000	-4,492,000	170,121,000	-1,422,000	-676,000	-676,000	-676,000	-676,000	-677,000	2,109,000			0
operating lease liabilities	-1,888,000	-1,805,000	-1,766,000	-1,705,000	-1,659,000	-1,584,000	-1,549,000	-1,493,000	-1,452,000	-1,002,000	-981,000	-928,000	-1,220,000	-1,179,000	-1,156,000	-939,000	-912,000	-880,000	-861,000	-821,000	-796,000	-765,000	-750,000	-712,000	-691,000	-663,000
net cash from operating activities	-46,012,000	-63,039,000	-43,648,000	-46,478,000	-27,468,000	-33,432,000	-33,239,000	-34,457,000	-37,257,000	85,522,000	-33,440,000	-25,646,000	-28,822,000	-39,873,000	-7,033,000	-28,184,000	-9,401,000	-44,375,000	-31,415,000	-20,172,000	-38,145,000	-26,250,000	-61,240,000	-43,681,000	-32,929,000	-50,381,000	-32,820,000	-29,010,000	71,394,000	-32,426,000	-22,754,000	-23,411,000	-20,088,000	-17,418,000	-13,294,000	-11,832,000	390,000	-7,136,000	-6,668,000
capex	-306,000	-165,000	-86,000	-383,000	-52,000	-417,000	-356,000	-198,000	-72,000	-489,000	-204,000	-457,000	-492,000	-208,000	-15,000	-98,000	-339,000	-108,000	-557,000	-65,000	-136,000	-580,000	0	-465,000	-1,599,000	-508,000	0	-3,389,000	-1,922,000	-1,164,000	-4,079,000	-5,606,000	-5,567,000	-3,635,000	-2,729,000	-1,275,000	0	-685,000	-970,000
free cash flows	-46,318,000	-63,204,000	-43,734,000	-46,861,000	-27,520,000	-33,849,000	-33,595,000	-34,655,000	-37,329,000	85,033,000	-33,644,000	-26,103,000	-29,314,000	-40,081,000	-7,048,000	-28,282,000	-9,740,000	-44,483,000	-31,972,000	-20,237,000	-38,281,000	-26,830,000	-61,240,000	-44,146,000	-34,528,000	-50,889,000	-32,820,000	-32,399,000	69,472,000	-33,590,000	-26,833,000	-29,017,000	-25,655,000	-21,053,000	-16,023,000	-13,107,000	390,000	-7,821,000	-7,638,000
cash flows from investing activities
purchases of property and equipment	-306,000	-165,000	-86,000	-383,000	-52,000	-417,000	-356,000	-198,000	-72,000	-489,000	-204,000	-457,000	-492,000	-208,000	-15,000	-98,000	-339,000	-108,000	-557,000	-65,000	-136,000	-580,000		-465,000	-1,599,000	-508,000		-3,389,000	-1,922,000	-1,164,000	-4,079,000	-5,606,000	-5,567,000	-3,635,000	-2,729,000	-1,275,000
net cash from investing activities	-306,000	-165,000	-86,000	-383,000	-52,000	-417,000	-356,000	-198,000	-72,000	-489,000	24,840,000	-501,000	24,614,000	-50,208,000	-15,000	-98,000	-339,000	-108,000	-557,000	-65,000	-136,000	-580,000	-1,346,000	-465,000	-1,599,000	-508,000	-3,463,000	-3,389,000	-1,922,000	-1,164,000	-4,081,000	-5,608,000	-5,569,000	-3,638,000	-5,328,000	-1,275,000	-874,000	-685,000	-970,000
cash flows from financing activities
proceeds from the issuance of ordinary shares, net of offering costs					0	14,038,000
proceeds from issuance of ordinary shares pursuant to the “at-the-market” equity program, net of offering costs	11,099,000	1,262,000
proceeds from the exercise of share options	594,000	2,451,000	2,060,000	690,000	106,000	123,000	388,000	35,000	85,000	1,000	136,000	50,000	0	37,000	0	50,000	0	200,000	19,000	702,000	10,000	10,000	757,000	253,000	116,000	1,481,000	646,000	1,351,000	1,560,000	1,553,000	604,000	80,000	37,000	206,000	97,000
proceeds from the espp	0	442,000	0	310,000	0	349,000	0	319,000	0	429,000	0	198,000	0	174,000
net cash from financing activities	11,693,000	4,155,000	34,981,000	203,746,000	653,000	14,510,000	93,962,000	1,670,000	1,849,000	35,053,000	55,000	17,000	65,800,000	1,316,000	33,793,000	8,349,000	5,045,000	8,641,000	19,000	142,523,000	11,382,000	614,000	757,000	253,000	-157,000	163,546,000	646,000	1,351,000	61,560,000	1,537,000	589,000	59,000	93,536,000	190,000	15,000	184,000	28,938,000	-16,000	102,736,000
effect of foreign exchange rates on cash, cash equivalents, and restricted cash	43,000	58,000		120,000	-81,000	-74,000
net decrease in cash, cash equivalents, and restricted cash	-34,582,000	-58,991,000
cash, cash equivalents, and restricted cash, beginning of period	0	305,838,000		0	0	204,050,000
cash, cash equivalents, and restricted cash, end of period	-34,582,000	246,847,000		157,005,000	-26,948,000	184,637,000
loss on disposal of property and equipment																													41,000	13,000
other non-current liabilities							0							868,000	-1,014,000	675,000	-68,000	-67,000	-946,000	-100,000	-101,000	-100,000	-72,000	-104,000	-142,000	-103,000	647,000	-38,000	-72,000	-14,000	598,000	-1,049,000	15,000	1,259,000	877,000	-4,000	-4,000	-5,000
proceeds from the sale of property and equipment											0	0																							0	0
purchase of short-term investments											0	-25,044,000	0	-50,000,000
proceeds from the maturity of short-term investments											25,044,000	25,000,000
proceeds from the issuance of ordinary shares as a part of the june 2022 offering, net of offering costs
proceeds from the issuance of ordinary shares as a part of the december 2023 offering, net of offering costs			0
proceeds from the issuance of ordinary shares as a part of the september 2024 offering, net of offering costs			27,858,000
proceeds from issuance pre-funded warrants as a part of the june 2022 offering, net of offering costs
proceeds from issuance pre-funded warrants as a part of the, september 2024 offering, net of offering costs
proceeds from issuance of ordinary shares pursuant to the gsk collaboration agreement
proceeds from issuance of ordinary shares pursuant to the at-the-market equity program														1,105,000	33,793,000	8,027,000	5,045,000	8,105,000	0	47,906,000	11,372,000	604,000
effect of foreign exchange rates on cash																															285,000	30,000	31,000	57,000	-115,000	173,000	-86,000	14,000	82,000
net increase in cash, cash equivalents and restricted cash							60,425,000	-33,017,000	-35,580,000	120,065,000					26,668,000				-31,865,000	122,309,000	-26,894,000	-26,210,000	-61,844,000	-43,891,000	-34,655,000	112,754,000	-35,665,000	-30,938,000
cash, cash equivalents and restricted cash, beginning of period							0	0	0	92,157,000	0	0	0	154,215,000	0	0	0	188,148,000	0	0	0	150,808,000	0	0	0	178,444,000	0	0	0	146,113,000
cash, cash equivalents and restricted cash, end of period							60,425,000	-33,017,000	-35,580,000	212,222,000	-8,451,000	-26,206,000	61,450,000	65,364,000	26,668,000	-19,944,000	-4,695,000	152,186,000	-31,865,000	122,309,000	-26,894,000	124,598,000	-61,844,000	-43,891,000	-34,655,000	291,198,000	-35,665,000	-30,938,000	130,944,000	114,103,000
supplemental disclosure of cash flow information:
offering costs in accounts payable at period end
increase in operating lease right-of-use assets and lease liabilities related to new lease
proceeds from the issuance of pre-funded warrants as a part of the september 2024 offering, net of offering costs
proceeds from the issuance of ordinary shares pursuant to the gsk collaboration agreement
proceeds from issuance of ordinary share pursuant to the “at-the-market” equity program, net of offering costs
net increase in cash, cash equivalents, and restricted cash				157,005,000	-26,948,000	-19,413,000
supplemental disclosure of cash flow information
offering costs related to the september 2024 offering in accrued expenses at period end
proceeds from issuance of ordinary share pursuant to the at-the-market equity program, net of offering costs
proceeds from issuance of ordinary shares, net of offering costs							58,951,000	0			-15,000	-229,000							0				0	0	-273,000	162,065,000	0	0			0	-5,000			0				0
proceeds from issuance pre-funded warrants, net of offering costs											-4,000	-64,000
proceeds from the sale property and equipment
proceeds from maturity of short-term investments
proceeds from issuance of pre-funded warrants, net of offering costs
proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs								1,316,000				62,000
effect of foreign exchange rates on cash, cash equivalents and restricted cash								-32,000	-100,000	-21,000		-76,000	-142,000	-86,000		-11,000	0	-120,000		23,000	5,000	6,000		2,000	30,000	97,000		110,000	-88,000	43,000
increase in operating lease right-of-use assets and lease liabilities related to lease extension												0
proceeds from issuance of ordinary shares										34,623,000
net decrease in cash, cash equivalents and restricted cash											-8,451,000	-26,206,000	61,450,000	-88,851,000			-4,695,000	-35,962,000												-32,010,000
at-the-market offering costs in accounts payable at period end																	-20,000	77,000
proceeds from the employee share purchase plan																272,000	0	336,000
proceeds from the employee share purchase program																			0
deferred follow-on offering costs in accounts payable and accrued expenses at period end																										280,000
amortization of lease incentive obligation																											-289,000	-232,000	-162,000	-107,000	-77,000	-65,000	-49,000	-17,000
net income on disposal of property and equipment
deferred rent																											73,000	230,000	283,000	387,000	387,000	1,023,000	1,153,000	1,031,000	194,000	117,000	118,000	136,000	92,000
deferred income taxes																															0				-742,000	135,000	48,000	-5,000	-146,000
purchases of property and equipment, net of tenant improvement allowances
payments on capital lease obligation																											0	0	0	-16,000	-15,000	-16,000	-15,000	-16,000	-15,000	-16,000	-15,000	-16,000	-14,000
prepaid expenses and other current assets																								-4,564,000	779,000	-637,000	-4,782,000	-1,429,000	-4,773,000	515,000	-2,615,000	-1,544,000	-530,000	-1,813,000	-871,000	1,603,000	-1,655,000	-414,000	-23,000
other non-current assets																								-2,561,000	-2,331,000	-2,577,000		-5,000	1,000	-11,000	-351,000							-53,000
net (gain) loss on disposal of property and equipment																											0
tax benefit related to share-based compensation																																			-243,000
costs associated with initial public offering																																			0
cash paid for taxes, net of refunds																												16,000	108,000	314,000
property and equipment purchases in accounts payable and accrued expenses at period end																												1,298,000	86,000	469,000	-1,080,000	-1,568,000	11,000	2,976,000	58,000
tenant improvements paid for by the landlord during the period																												1,499,000	433,000	800,000	0
tenant improvements to be reimbursed by the landlord																												628,000	2,395,000	1,279,000
adjustments to reconcile net income to net cash flows used in operating activities:
depreciation and amortization																																			259,000	188,000	184,000	153,000	132,000
increase in restricted cash																															-2,000	-2,000	-2,000	-3,000					0
proceeds from government grant reimbursements for property and equipment																																							0
proceeds from initial public offering, net of offering costs and underwriter commissions
proceeds from issuance of series b preferred shares, net of offering costs																																							-111,000
proceeds from government grant																																							0
net increase in cash and cash equivalents																															-25,961,000	-28,930,000	67,910,000	-20,809,000	-18,722,000
cash and cash equivalents at beginning of period																															0	0	0	150,293,000	0
cash and cash equivalents at end of period																															-25,961,000	-28,930,000	67,910,000	129,484,000	-18,722,000
deferred offering costs in accounts payable and accrued expenses at period end
cash paid for interest
equipment acquired for capital lease obligation
deferred follow-on offering costs in accrued expenses at period end
increase in the lease incentive obligation during the period																																		1,082,000
conversion of related party notes payable into ordinary and series a preferred shares
reclassification of series a preferred shares from permanent equity to temporary equity
increase in accounts payable for initial public offering costs
payments associated with initial public offering
proceeds from the exercise of stock options
net increase in cash																																					28,368,000	-7,823,000	95,180,000
cash at beginning of period																																					0	161,220,000	0
cash at end of period																																					28,368,000	153,397,000	95,180,000
property and equipment purchases in accounts payable at period end																																					854,000	185,000
•
purchase of property and equipment																																						-685,000	-970,000
outstanding as of january 1, 2016																																						2,215,342,000
granted																																						317,000,000
cancelled or forfeited																																						-1,616,000
outstanding as of march 31, 2016																																						2,530,726,000
options exercisable as of march 31, 2016																																						848,223,000
options vested and expected to vest as of march 31, 2016																																						2,434,625,000
proceeds from sale of property and equipment
proceeds from related party notes payable
payment of related party notes payable
equipment under acquired for capital lease obligation
conversion of ordinary shares into series a preferred shares
property and equipment purchases in accounts payable
increase in accrued expenses for deferred offering costs
furniture and equipment																																							-2,859,000
leasehold improvements
total
less accumulated depreciation and amortization
property and equipment

We provide you with 20 years of cash flow statements for Wave Life Sciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Wave Life Sciences stock. Explore the full financial landscape of Wave Life Sciences stock with our expertly curated income statements.

The information provided in this report about Wave Life Sciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.